Breast cancer (BC) is one of the major causes of death worldwide. It is the most common cause of death before the age of 70 years. The incidence and mortality of BC are rapidly increasing, posing great challenges to the health system and economy of every nation. A cross-sectional analytical study was conducted at the Department of Pathology and Clinical Laboratory of the French Medical Institute for Mothers and Children (FMIC) to demonstrate the association of human epidermal growth factor receptor 2 (Her2/Neu) and estrogen receptor (ER)/ progesterone receptor (PR) with clinical as well as pathological parameters among women with BC. A consecutive nonprobability sampling method was used for this study over a span of one and a half years. One hundred twenty participants diagnosed with breast cancer were included in the study. The mean age at diagnosis was 44.58 ± 11.16 years. Out of the total patients, 68 (56.7%) were above 40 years old, 108 (90%) were married, 94 (78.3%) were multiparous, and 88 (73.3%) had a history of breastfeeding. 33.3% of cases were within the age range of menopause (40–50 years). The positive expression rates of ER, PR, and Her2/neu were found to be 48.8%, 44.6%, and 44.6%, respectively, and Her2/neu overexpression was found to be higher among ER/PR-negative cases. In our study, we demonstrated that among Afghan women, grade II invasive ductal carcinoma, not otherwise specified, was the most common type of BC and frequently affected women above the age of 40. We also revealed that the percentage of negative ER (50.4%), negative PR (54.4%), and concordant ER/PR-negative cases were high compared to other possibilities. Additionally, the study revealed that expression of Her2/neu was in contrast with the expression of ER and PR receptors. The findings of our study still support the importance of performing immunohistochemical stains for hormonal receptor classification in terms of better clinical outcomes and prognosis.

中文翻译：

---

激素受体和人表皮生长因子受体-2/neu 表达与乳腺癌临床病理因素的关联：阿富汗喀布尔一家三级护理医院的横断面研究

乳腺癌（BC）是全世界死亡的主要原因之一。它是 70 岁之前最常见的死亡原因。 BC的发病率和死亡率迅速上升，给各国卫生系统和经济带来巨大挑战。法国母婴医学研究所 (FMIC) 病理学和临床实验室进行了一项横断面分析研究，以证明人表皮生长因子受体 2 (Her2/Neu) 和雌激素受体 (ER) 之间的关联/ 孕激素受体 (PR) 与 BC 女性的临床和病理参数。这项研究采用了为期一年半的连续非概率抽样方法。该研究包括一百二十名被诊断患有乳腺癌的参与者。诊断时的平均年龄为 44.58 ± 11.16 岁。患者中，40岁以上68例（56.7%），已婚108例（90%），经产94例（78.3%），有母乳喂养史88例（73.3%）。 33.3%的病例处于更年期年龄范围内（40-50岁）。 ER、PR和Her2/neu的阳性表达率分别为48.8%、44.6%和44.6%，且ER/PR阴性病例中Her2/neu过度表达较高。在我们的研究中，我们证明，在阿富汗女性中，未另行说明的 II 级浸润性导管癌是最常见的 BC 类型，并且经常影响 40 岁以上的女性。我们还发现，阴性 ER 的百分比（50.4%） ）、PR 阴性（54.4%）和一致 ER/PR 阴性病例与其他可能性相比较高。此外，研究表明 Her2/neu 的表达与 ER 和 PR 受体的表达相反。我们的研究结果仍然支持对激素受体分类进行免疫组织化学染色对于更好的临床结果和预后的重要性。